Frequently Asked Questions
The market is segmented based on , By Treatment (Enzyme Replacement Therapy and Stem Cell Therapy), Disease Type (Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type IV A, Mucopolysaccharidosis Type VI, Mucopolysaccharidosis Type VII and Others), Route of Administration (Intravenous, and Intracerebroventricular (ICV)), End User (Hospitals, Specialty Clinics and Others) – Industry Trends and Forecast to 2031.
.
The Global Mucopolysaccharidosis Market size was valued at USD 2.27 USD Billion in 2023.
The Global Mucopolysaccharidosis Market is projected to grow at a CAGR of 8.9% during the forecast period of 2024 to 2031.
The major players operating in the market include Takeda Pharmaceutical Company Limited (Japan), BioMarin (U.S.), Ultragenyx Pharmaceutical (U.S.), Sarepta Therapeutics (U.S.), Inventiva (France), GC Pharma (South Korea), JCR Pharmaceuticals Co Ltd. (Japan), REGENXBIO Inc. (U.S.), Sangamo Therapeutics (U.S.), Denali Therapeutics (U.S.), Bioasis Technologies Inc. (Canada), Paradigm Biopharmaceuticals Ltd. (Australia).
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America.
